Datamonitor Healthcare has identified the following key highlights from the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, which was held between 30 May and 3 June 2014:
Results from early-phase clinical trials of AstraZeneca’s AZD9291
Imbruvica's (Ibrutinib; Pharmacyclics/Janssen Biotech) Phase III RESONATE results
Results from the Phase II ROMULUS trial
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: